As of December 2009, there were 10.9 million individuals enrolled in Medicare Advantage (MA) plans. That’s more than a million member increase from 2008. And although a million member bump and an annual growth rate of 10.4 percent are respectable, according to A.M. Best, the credit rating organization, it’s lower than the growth rate of the prior two years, when the rate was in the high teens.

Medicare Advantage did not grow as fast from 2008 to 2009 as it had in previous years because some plans stopped offering a private fee-for-service (PFFS) product, according to the company’s publication, 2010 Special Report: U.S. Health — Review & Preview.

A PFFS plan is an MA health plan, offered by a state-licensed, risk-bearing entity that has a yearly contract with the Centers for Medicare & Medicaid Services to provide beneficiaries with all of their Medicare benefits plus any additional benefits that the company decides to provide.

Because the Medicare Improvements for Patients and Providers Act of 2009 requires companies that offer the PFFS product to build a provider network for their members (effective Jan. 1, 2011) — and in view of the widely known shortage of physicians — plans have been jettisoning the PFFS product, with exits taking effect Jan. 1, 2010 and 2011.

Dropping the product has caused some individuals to switch from a PFFS product to another type of plan, either a preferred provider organization or a health maintenance organization, according to the report.

As MA plans discard PFFS products, membership hits a snag

Medicare enrollment (in thousands)

Source: A.M. Best. 2010 Special Report: U.S. Health — Review & Preview. Feb. 8, 2010.

United Healthcare

Humana

WellPoint

Coventry Health Care

Aetna

Health Net

UniversalHealth

WellCare Health Plans

Triple-S Management

Cigna

Amerigroup

Molina Healthcare

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.